<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550702</url>
  </required_header>
  <id_info>
    <org_study_id>202006091RIND</org_study_id>
    <nct_id>NCT04550702</nct_id>
  </id_info>
  <brief_title>Predictors for Retreatement of OAB After DC Mirabegron</brief_title>
  <official_title>Predictor for Re-treatment of Overactive Bladder Syndrome After Discontinuation of Mirabegron Treatment for Female Overactive Bladder Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to&#xD;
      decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB,&#xD;
      especially for those women who need retreatment is undetermined. Thus, the aim of this study&#xD;
      was to elucidate factors predicting retreatment of female OAB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The medical records, including pad testing, urodynamic studies, lower urinary tract symptoms&#xD;
      related questionnaires and bladder diaries of all consecutive women with OAB, who visited&#xD;
      urogynecologic clinics in a tertiary referral center, were reviewed. Persistence interval was&#xD;
      defined from the date of prescription of mirabegron to the date of discontinuation of&#xD;
      mirabegron treatment. Statistical analysis was performed with Kaplan-Meier estimator.&#xD;
      Multivariable Cox proportional-hazard model with all variables with p &lt; 0.25 in the&#xD;
      univariate analysis was performed to predict OAB retreatment probability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent OAB</measure>
    <time_frame>January 2015 to July 2019</time_frame>
    <description>Recurrent OAB with needs to retreatment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Recurrence of Overactive Bladder Syndrome</condition>
  <arm_group>
    <arm_group_label>Women received Mirabegron</arm_group_label>
    <description>Women with overactive bladder syndrome received Mirabegron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron 25mg</intervention_name>
    <description>Mirabegron 25 mg per day</description>
    <arm_group_label>Women received Mirabegron</arm_group_label>
    <other_name>Betmiga</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with overactive bladder syndrome who completed urodynamic study and bladder diary and&#xD;
        received Mirabegron 25 mg per day&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with overactive bladder syndrome&#xD;
&#xD;
          -  Women complete urodynamic study and bladder diary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Incomplete data&#xD;
&#xD;
          -  Loss of follow-up&#xD;
&#xD;
          -  Acute or chronic urinary tract infection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho-Hsiung Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. doi: 10.1002/nau.20798. Review.</citation>
    <PMID>19941278</PMID>
  </results_reference>
  <results_reference>
    <citation>Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009 Apr;103 Suppl 3:4-11. doi: 10.1111/j.1464-410X.2009.08371.x.</citation>
    <PMID>19302497</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsiao SM, Lin HH. Medical treatment of female overactive bladder syndrome and treatment-related effects. J Formos Med Assoc. 2018 Oct;117(10):871-878. doi: 10.1016/j.jfma.2018.01.011. Epub 2018 Feb 15. Review.</citation>
    <PMID>29398096</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsiao SM, Su TC, Chen CH, Chang TC, Lin HH. Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects. Maturitas. 2014 Sep;79(1):65-9. doi: 10.1016/j.maturitas.2014.06.001. Epub 2014 Jun 20.</citation>
    <PMID>25022469</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsiao SM, Liao SC, Chen CH, Chang TC, Lin HH. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects. Maturitas. 2014 Dec;79(4):428-34. doi: 10.1016/j.maturitas.2014.08.009. Epub 2014 Sep 3.</citation>
    <PMID>25238744</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsiao SM, Chang TC, Chen CH, Wu WY, Lin HH. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder. Menopause. 2017 Jan;24(1):100-104. doi: 10.1097/GME.0000000000000730.</citation>
    <PMID>27648660</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overactive bladder syndrome</keyword>
  <keyword>beta-3 agonist</keyword>
  <keyword>retreatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will be shared under reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

